title: Continuous administration of landiolol reduced QT dispersion in postoperative patients.
abstract: OBJECTIVE
  To determine the changes in QT dispersion (QTD) in the standard electrocardiogram (ECG) of postoperative patients and the effect of landiolol on QTD.
  
  
  METHODS
  Randomized, prospective, double-blinded study.
  
  
  METHODS
  40 postsurgical patients.
  Patients were allocated to three groups: Control group patients (Group C) were administered saline and patients in the landiolol groups (Group L2 and Group L5) were infused landiolol 2 μg/kg/min and 5 μg/kg/min, respectively. All infusions were started at midnight and discontinued at 6 o'clock in the morning.
  
  
  METHODS
  Heart rate (HR), systolic (SBP) and diastolic (DBP) invasive blood pressure, and ECG were recorded at 0 (immediately before infusion), at 3 o'clock, and 6 o'clock (immediately before termination). The ECG wave was recorded electronically and QTD was analyzed using PC software. Heart rate, blood pressure, QT interval, and QTD were compared as changes from baseline values.
  
  
  RESULTS
  In Groups L2 and L5, HR was significantly decreased, approximately 10 bpm. Both SBP and DBP showed a decreasing trend at 3 o'clock. Absolute QT interval was prolonged in all groups; however, the decrease in QTD occurred in Group L5.
  
  
  CONCLUSIONS
  Continuous administration of landiolol prevents the increase in QTD found on the morning in postoperative patients. Landiolol demonstrated a possible antiarrhythmic effect by improving the imbalance of repolarization.
authors.affiliation: Department of Anesthesia, Koseiren Enshu Hospital, Hamamatsu, 430-0929, Japan.
authors.forename: Katsumi
authors.initials: K
authors.lastname: Suzuki
authors.affiliation: Department of Emergency Medicine, Nagoya University Hospital, Showa-ku, Nagoya City, Aichi, 466-8550, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Numaguchi
authors.affiliation: Department of Emergency Medicine, Nagoya University Hospital, Showa-ku, Nagoya City, Aichi, 466-8550, Japan. Electronic address: yuadachi@med.nagoya-u.ac.jp.
authors.forename: Yushi U
authors.initials: YU
authors.lastname: Adachi
authors.affiliation: Department of Anesthesia and Resuscitation, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, 431-3192, Japan.
authors.forename: Yukako
authors.initials: Y
authors.lastname: Obata
authors.affiliation: Department of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Hatano
authors.affiliation: Department of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
authors.forename: Tadashi
authors.initials: T
authors.lastname: Ejima
authors.affiliation: Department of Anesthesia and Resuscitation, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, 431-3192, Japan.
authors.forename: Shigehito
authors.initials: S
authors.lastname: Sato
authors.affiliation: Department of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Matsuda
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000503:physiopathology / Q000517:prevention & control*; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage* / Q000627:therapeutic use; D011182:Postoperative Care / Q000379:methods; D011183:Postoperative Complications / Q000503:physiopathology / Q000517:prevention & control*; D011446:Prospective Studies; D014508:Urea / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D009025:Morpholines; C077049:landiolol; D014508:Urea
keywords: Antiarrhythmogenic effect; Beta blockers; Landiolol; QT dispersion